• Clinical Introduction
• 49 min
  1. Frontotemporal dementia

  • Prof. Bruce Miller
• 57 min
  2. Parkinson disease

  • Prof. Stanley Fahn
• 35 min
  3. Atypical parkinsonian syndromes

  • Dr. David Burn
• 40 min
  4. Huntington's disease

  • Prof. Roger Barker
• Neuroimaging
• 22 min
  5. Molecular brain imaging (PET) in diseases with dementia

  • Prof. Karl Herholz
• Pathology, Genetic and Molecular Aspects (1)
• 42 min
  6. A molecular understanding of Alzheimer's disease

  • Prof. John Hardy
• 33 min
  7. Neuropathology of neurodegenerative disorders

  • Prof. Jillian Kril
• 52 min
  8. The role of MAPT (Tau) in neurodegenerative disease: one bullet with many triggers

  • Dr. Michael Hutton
• 12 min
  9. Ubiquitination and Alzheimer related disorders

  • Prof. John Mayer
• Pathology, Genetic and Molecular Aspects (2)
• 46 min
  10. The molecular biology of Huntington's disease

  • Prof. David C. Rubinsztein
• 46 min
  11. Metals, oxidative stress and neurodegeneration

  • Prof. Ashley Bush
• Latest Developments in the Field
• 46 min
  12. Animal models of tauopathy

  • Prof. David Westaway
• 61 min
  13. Parkinson's disease and transplants

  • Prof. Roger Barker
• Archived Lectures *These may not cover the latest advances in the field
• 29 min
  14. Neuropathology of neurodegenerative disorders

  • Prof. Jillian Kril
• 36 min
  15. Motor neurone disease: molecular basis

  • Prof. Kevin Talbot
• 51 min
  16. Alzheimer's disease (AD)

  • Prof. John Hodges
• 53 min
  17. Frontotemporal dementia syndromes

  • Prof. John Hodges
• 38 min
  18. Motor neurone disease: clinical aspects

  • Prof. Kevin Talbot
• 26 min
  19. Neuro-imaging in dementia: using MRI in routine work-up

  • Prof. Philip Scheltens
• 53 min
  20. Prion diseases

  • Prof. Pierluigi Gambetti
• 38 min
  21. Mitochondrial disorders and neurodegeneration

  • Prof. Anthony Schapira
• 21 min
  22. Neurodegenerative disease: expression levels of normal sequence pathogenic proteins contribute to risk of disease

  • Prof. John Hardy
• 44 min
  23. Mutations in parkinsonian syndromes

  • Dr. Andrew Singleton
• 42 min
  24. Experimental therapies in Alzheimer's disease: the development and use of mouse models

  • Prof. David Westaway
• 32 min
  25. Frontotemporal dementia

  • Prof. Bruce Miller

Printable Handouts

PDF

Navigable Slide Index

1. Intro slide
2. Models of AD
3. I - key facets of AD pathogenesis
4. Pathogenic pathways
5. A-beta peptide
6. Neurofibrillary tangles
7. AD genes
8. A-beta derived by APP endoproteolysis
9. BACE 1 is beta-secretase
10. Gamma-cleavage of APP
11. Gamma-secretase has many substrates
12. Two ways for APP processing
13. Tauopathies
14. Simple pathogenic pathway for AD
15. II - animal models of AD
16. Why transgenic and why mice?
17. Technical aspects of transgenesis
18. Creation of transgenic APP mice
19. Amyloid peptide in aging mice
20. Morris water maze test
21. Learning acquisition
22. Creation of NFT-depositing mice
23. Tangles, frontal cortex
24. Astrocytic pathologies
25. Encoded protein effects neuroanatomical position
26. From A-beta to tau pathology
27. III - new insights into pathogenesis
28. Testing effects on A-beta
29. Copper and A-beta
30. Mutant mice with elevated copper
31. Effects of copper on CSF A-beta
32. Elevated copper and reduced plaque
33. Conclusions
34. Relationship between copper and pathogenesis
35. Presenilin-1 transgenics
36. Presenilin-2 transgenics
37. PS1/PS2 and APP fragments
38. IV - A-beta directed therapies
39. AD vaccination studies
40. Immunization with A-beta 1-42
41. A-beta immunization of TgCRND8 mice
42. Immunization 2000-2002
43. A-beta antibodies inhibit fibril formation
44. Epitope mapping of A-beta
45. Immunotherapy of "Alzheimer" mice
46. Pathogenic pathways
47. AD pathogenesis scheme
48. Acknowledgements
49. References

Topics Covered

• Animal models and AD research
• Role in identifying pathological pathways, biomarkers and candidate therapies
• Design of models and associated technical parameters
• Process of transgenesis
• Developing mouse models for beta-amyloid precursor protein mutations
• TgCRND8 mice
• Transgenic approaches for investigating Tau mutations
• Exploring environmental modifiers of beta-amyloid pathobiology
• Candidate chemical risk-factor for sporadic AD
• Potential of ''smart'' beta-amyloid-directed interventions

Links

Series:

• Neurodegenerative Diseases

Categories:

• Clinical Practice
• Methods
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. David Westaway has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.